AVA 011
Alternative Names: AVA-011Latest Information Update: 28 Jun 2024
At a glance
- Originator Arbele; Avalon GloboCare
- Class Antineoplastics; CAR-NK cell therapies; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in Hong Kong (Parenteral)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in USA (Parenteral)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in Hong Kong (Parenteral)